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Induction Therapy (IT) of non small cell lung cancer (NSCLC) 
with reliable response rate and low treatment related morbidity 
and mortality, a phase II study
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Background: Although the only known curative therapy for NSCLC 
remains to be surgical intervention, the survival results leave much to 
be desired. We have collaborated for the past decades in developing 
effective IT for the loco-regional NSCLC. In order to improve the over 
all survival using IT, we need to look for a regimen which produces 
a reliable response rate with a low treatment related morbidity and 
mortality. 
Methods: Patients with NSCLC in clinical stages IB, IIA and B, IIIA 
and B received a course of IT with 20 Gy of radiation therapy in 2 
weeks. This was followed by 2 courses of chemotherapy consisting of 
paclitaxel 180 mg/m2, cisplatin 45 mg/m2, and ifosfamide 1,000 mg/m2. 
Two to three weeks after the chemotherapy, the patients were reevalu-
ated and if suitable underwent surgical therapy.
Results: From March 2000 to July 2004, a total of 35 patients were en-
tered into the study.The overall response rate was 82.86% (95% conﬁ-
dence interval, 66.35-94.5%). Complete response (CR) was 20 % (95% 
conﬁdence interval, 8.44-36.94%). Twenty ﬁve patients subsequently 
had the surgical resection (7 patients with CR was not operated). The 
median follow up is 30 months. In 12 patients with stage IB, IIA and 
B, the median survival is 61 months and the 3 year survival was 63 % 
(Fig 1). In 23 patients with stage IIIA and B the median survival was 26 
months and the 3 year survival was 30 % (Fig 2).
There was no post operative mortality, but was one mortality of post 
radiation therapy pneumonitis. 
Conclusions: The regimen produced a high-response rate with low 
treatment related morbidity and mortality. Therefore, it is a suitable 
regimen for IT, specially for the stage IB, IIA and B NSCLC.
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Radiation therapy concurrent with cisplatin and vinblastine in 
locally advanced non small cell lung cancer
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Background: Thoracic radiotherapy plays pivotal role in the treatment 
of advanced NSCLC. Over the years, new treatment schedules have 
been evaluated, but an ideal treatment schedule is still awaited. The 
present trial was designed to evaluate the efﬁcacy of Cisplatin (C) and 
Vinblastine (V) concurrent with RT compared to RT alone in locally 
advanced unresectable NSCLC.
Methods: Sixty patients of stage III NSCLC were enrolled into the 
study. Patients were divided into 2 groups of 30 patients each. The 
CVRT group patients received external radiotherapy 60Gy in 30 frac-
tions, 5 days a week over 6 weeks by conventional daily dose frac-
tionation schedule concurrently with Cisplatin 75mg/m2 intravenously 
given starting on day 1 of radiation therapy for 5 courses at 3 weeks 
interval and vinblastine 5mg/m2 given weekly for 5 courses starting on 
day 1 of radiation. RT group patients received only conventional exter-
nal radiotherapy 60Gy in 30 fractions, 5 days a week over 6 weeks.
Results: At the end of treatment tumor response was observed in 
53.5% patients (20% CR; 33.5% PR) in CVRT group as compared to 
47% patients (all PR) in the RT group. Severe toxicities observed were 
esophagitis (grade 3) in 6 patients (4 in CVRT group & 2 in RT group 
and leucopenia in 5 patients in CVRT group. One year survival rates 
are 40% and 51% in RT and CVRT groups respectively.
Conclusion: In conclusion chemotherapy with Cisplatin and vinblas-
tine given concurrently with thoracic radiation has encouraging activity 
and is a relatively safe regimen.
